Empfehlung
13,3
Stark Verkaufen
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,72% (Stand: 28.02.2026)
Score-Verlauf (90 Tage)
Stammdaten
Unternehmen
| Name | Vaxcyte, Inc. |
|---|---|
| Ticker | PCVX |
| CIK | 0001649094 |
Branche
| SIC-Code | 2836 |
|---|---|
| Beschreibung | Biological Products, (No Diagnostic Substances) |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | Vaxcyte, Inc. |
Status
| Zuletzt geprüft | 2026-03-20 22:21:18.095044 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-11 | Cowan Elvia | Officer, SVP, Finance & CAO | Open Market Sale | -2,500 | 58.59 | -146,481.75 | -57,7% | |
| 2026-03-10 | Wassil Jim | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -4,968 | 59.16 | -293,906.88 | -115,9% | |
| 2026-03-10 | Wassil Jim | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -2,427 | 58.32 | -141,532.93 | -55,8% | |
| 2026-03-10 | Wassil Jim | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -4,968 | 59.16 | -293,906.88 | -115,9% | |
| 2026-03-10 | Wassil Jim | Officer, CHIEF OPERATING OFFICER | Open Market Sale | -2,427 | 58.32 | -141,532.93 | -55,8% | |
| 2025-12-31 | Dhaliwal Harpreet S. | Officer, Chief Technical Ops Officer | Open Market Sale | -9,743 | 46.69 | -454,890.93 | -179,3% | |
| 2025-12-23 | Cowan Elvia | Officer, SVP, FINANCE | Open Market Sale | -6,716 | 47.94 | -321,931.46 | -126,9% | |
| 2025-12-23 | Cowan Elvia | Officer, SVP, FINANCE | Open Market Sale | -4,907 | 47.90 | -235,040.39 | -92,7% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.